The report: ‘The European Union summary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2016’, highlights emerging issues and confirms antimicrobial resistance (AMR) as one of the biggest threats to public health, mainly by reducing the effectiveness of treatment options.
Zoonoses are infections that are transmissible between animals and humans. Infections can be acquired directly from animals, from environmental exposure or through the ingestion of contaminated foodstuffs.
The severity of these diseases in humans varies from mild symptoms to life-threatening conditions.
Zoonotic bacteria that are resistant to antimicrobials are of particular concern, as they might compromise the effective treatment of infections in humans.
Data from the European Union (EU) Member States (MSs) are collected and analysed to monitor the occurrence of antimicrobial resistance (AMR) in zoonotic bacteria isolated from humans, animals and food in the EU.
For 2016, 27 MSs reported data on AMR in zoonotic bacteria to EFSA, and 23 MSs submitted data to ECDC. In addition, three other European countries provided information.
Mike Catchpole, chief scientist, ECDC, said it is concerned to see Salmonella and Campylobacter bacteria in humans show high levels of antimicrobial resistance.
“The fact we keep detecting multidrug-resistant bacteria means the situation is not improving. We need to investigate the origins and prevent the spread of highly resistant strains, such as ESBL-producing Salmonella Kentucky,” he added.
Extended-spectrum beta-lactamase (ESBL)-producing S. Kentucky cannot be treated with critically important antibiotics and are also resistant to other antimicrobials used in human medicine, such as ampicillin, gentamicin and tetracyclines.
Vytenis Andriukaitis, European Commissioner for Health and Food Safety confirmed levels of antimicrobial resistance still differ significantly from one EU country to another but to ‘win the fight’, we need to work together and implement stringent policies on the use of antibiotics across sectors.
“It is vital we all renew our commitment to fight antimicrobial resistance by focusing on the key areas set out in the EU One Health Action Plan against antimicrobial resistance,” said Andriukaitis.
Among the findings, based on data from 2016, are detection of resistance to carbapenems in poultry, an antibiotic which is not authorized for use in animals, and of ESBL-producing Salmonella Kentucky with high resistance to ciprofloxacin in humans, which was reported for the first time in four countries.
Marta Hugas, chief scientist, EFSA, said: “The detection of resistance to carbapenems in poultry and to linezolid in methicillin-resistant Staphylococcus aureus in pigs is alarming because these antibiotics are used in humans to treat serious infections. It is important that risk managers follow-up on these findings.”
The main findings in the 270-page report can be found here and in the summary below.
- One out of four Salmonella infections in humans are caused by Salmonella bacteria that show resistance to three or more antimicrobials commonly used in human and animal medicine. The proportion is significantly higher in S. Kentucky and S. Infantis (76.3 and 39.4% respectively).
- For the first time, ESBL-producing S. Kentucky with high resistance to ciprofloxacin was detected in four countries. This type of bacteria cannot be treated with critically important antibiotics.
- Campylobacter bacteria, which cause the most common food-borne disease in the EU, show high resistance to widely used antibiotics (ciprofloxacin resistance 54.6% in C. jejuni and 63.8% in C. coli; tetracyline resistance 42.8% in C. jejuni and 64.8% in C. coli). The levels of resistance increased in two of the three analysed antibiotics (ciprofloxacin and tetracycline), but combined resistance to the critically important antimicrobials is stable and overall low (0.6% in C. jejuni and 8.0% in C. coli). In some countries, however, at least one in three C. coli infections were multidrug-resistant to important antibiotics, leaving very few treatment options for severe infections.
Animals and foods
- Resistance to carbapenem antibiotics was detected at very low level in poultry and in chicken meat in two Member States (fifteen E. coli bacterial isolates). Carbapenems are used to treat serious infections in humans and are not authorised for use in animals.
- Two livestock-associated methicillin-resistant Staphylococcus aureus bacterial isolates found in pigs were reported to be linezolid-resistant. Linezolid is one of the last-resort antimicrobials for the treatment of infections caused by highly resistant MRSA.
- Combined clinical resistance to critically important antimicrobials was observed at low to very low levels in Salmonella (0.2%), Campylobacter (1%) and E. coli (1%) in poultry.
- Resistance to colistin was observed at low levels (2%) in Salmonella and E. coli in poultry.
- Prevalence of ESBL-producing E. coli in poultry varies markedly between the Member States, from low (less than 10%) to extremely high levels (more than 70%). Bacteria that produce ESBL enzymes show multi-drug resistance to β-lactam antibiotics – a class of broad spectrum antibiotics that includes penicillin derivatives, cephalosporins and carbapenems. This is the first time that the presence of extended-spectrum beta-lactamase (ESBL)-producing E. coli was monitored in poultry and poultry meat.
Source: EFSA and ECDC
Publication: EU summary report on AMR in zoonotic bacteria